CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed® announced today that the first patients have been enrolled in the COMPaSS™ study. COMPaSS, Clinical Outcome Measures in Personalized aprevo® Spine Surgery, is a multi-center post market prospective observational registry. The study will collect data on patients with degenerative spinal conditions and are treated surgically with Carlsmed aprevo devices and will track outcomes for a period of two years.
“The COMPaSS study will generate first-of-its-kind preoperative intervertebral data for surgical planning and personalized aprevo designs along with postoperative metrics for spinal alignment and clinical outcomes,” commented Roland Kent, MD, the COMPaSS study Chief Investigator. “After observing excellent initial results with aprevo in my own patients, I am excited to collaborate with colleagues across the country to verify durability of achieved spinal alignment and assess patient satisfaction over the next two years.”
“The COMPaSS study further advances Carlsmed’s mission to collect data and improve outcomes of patients through the power of personalized spine surgery,” stated Mike Cordonnier, CEO of Carlsmed. “The ongoing commitment to real-world data collection will continue to drive the transformation to deep personalization of surgical devices and procedures.”
The landmark COMPaSS study will evaluate spinal alignment, complications, and patient reported outcome measures for a wide variety of patients with degenerative spinal conditions.
Carlsmed’s mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. Carlsmed uses patient data and proprietary digital technologies to create aprevo spine fusion devices that are both patient specific and surgeon specific. For more information, visit carlsmed.com or contact us at firstname.lastname@example.org.